SPHK1 and breast cancer: It is well accepted that IGF1R can regulate ER, and SphK1 is regulated by estrogen, in breast cancer [13, 47, 48], hence the therapeutic implication that co-targeting them may be clinically effective in ER-positive breast cancer.